Bliss GVS Pharma jumps 20% in 2026 on 43% stake buy

What triggered the sharp move in Bliss GVS Pharma

Shares of Bliss GVS Pharma surged to an upper circuit of 20% on Tuesday after the company said Anupam Rasayan would acquire a large stake in the drugmaker. The announcement put Bliss GVS Pharma in focus across both NSE and BSE, with trading activity reflecting a sharp re-rating on the day. On BSE, the stock hit a record high of ₹381.10, rising 20% against the previous close of ₹317.60. The day’s move also came alongside a jump in momentum indicators tracked by traders.

The deal value and the open offer structure were the key drivers behind the price action. Bliss GVS Pharma’s market capitalisation was reported at about ₹4,031 crore, reflecting the day’s surge. The stock’s rally also pushed it into an “overbought” zone on charts, with the Relative Strength Index (RSI) rising to 74.4. RSI above 70 is widely read as an overbought signal.

Deal overview: Anupam Rasayan to buy 43% stake

Bliss GVS Pharma said leading chemical manufacturer Anupam Rasayan would acquire a 43% stake in the company for ₹1,369.51 crore. Anupam Rasayan India Managing Director Anand Desai said the company had entered into a definitive agreement to acquire 43.3% to 48.2% equity stake and that it would make an open offer to public shareholders.

The acquisition, as described in the update, positions Anupam Rasayan to become a significant shareholder in a formulations-focused pharmaceutical company. Bliss GVS Pharma develops and exports formulations including suppositories, tablets, capsules and injectables. The combination also links Anupam Rasayan’s chemical manufacturing base with finished dosage formulations.

Mandatory open offer: price and size

The acquisition of 43% stake will trigger a mandatory open offer for an additional 26% stake. The open offer price was stated at ₹299 per share. The offer structure is important for minority shareholders because it sets a defined exit price and clarifies the next step under takeover regulations once a control threshold is crossed.

For investors tracking the stock around the announcement, the open offer price sits below the record intraday level cited for Tuesday. That gap, alongside the sharp circuit move, highlighted that the immediate reaction in the market was driven more by control-change expectations and strategic fit than by the tender price itself.

Funding plan disclosed for the acquisition

Anupam Rasayan said the acquisition would be funded via a ₹300 crore term loan. The remaining amount will be financed via a non-controlling, non-voting equity instrument. This disclosure matters because it gives a clearer view of the funding mix, separating debt from an equity-linked component while also specifying that the instrument is non-voting.

The announcement did not provide further detail on the exact instrument type in the information available, but it did specify the key attributes: non-controlling and non-voting.

Strategic rationale: integration across the value chain

Desai said the transaction would “strategically strengthen” Anupam Rasayan’s presence across the pharmaceutical value chain, spanning key starting materials to finished dosage formulations. The company also said the combined entity would create an integrated pharmaceutical manufacturing platform with deeper backward integration.

Anupam Rasayan added that the platform would have expanded reach in regulated markets, including Europe and the United States. The company linked this to its earlier acquisition of Jayhawk, which it said would aid the expanded reach.

Stock performance and technical cues on the day

The market response was immediate. Bliss GVS Pharma hit a record high of ₹381.10 on BSE, up 20% over the previous close of ₹317.60. Separately, intraday data in the provided market snapshot showed the stock trading at ₹317.55 (+5.73%) as of May 25, 2026 at 9:31 pm IST, reflecting the volatility and the timing differences in price snapshots around the event window.

The stock’s RSI was reported at 74.4, which is above the commonly used 70 threshold that signals overbought conditions. Such readings typically indicate strong recent momentum, though they can also suggest heightened near-term risk of pullbacks. The rally also occurred with reported volume of 98.48 lakh shares in one of the price summaries.

Key numbers at a glance

Company snapshot: business, valuation, and profits reported

Bliss GVS Pharma is listed on both NSE and BSE and is classified as a small-cap stock in the pharma sector in the provided data. Its business includes development, manufacturing and marketing of pharmaceutical formulations, and it exports multiple dosage forms.

On valuation and financial metrics available in the text, the company’s price-to-earnings ratio was listed at 26.29x. The dividend yield was shown at 0.33% in one snapshot. The company’s Q4 FY2025-26 net profit was reported at ₹35.58 crore, up 128.96% compared with the same period last year, and up 52.9% on a quarter-on-quarter basis. Another data point in the text stated that Bliss GVS Pharma reported a net profit of ₹129.13 crore in 2026.

Market impact: what investors are weighing

The announcement placed Bliss GVS Pharma at the centre of a control transaction, with a clear funding plan and a defined open offer. For Anupam Rasayan, the stated rationale is end-to-end integration, linking starting materials to finished dosage formulations, and expanding presence in regulated markets such as Europe and the United States.

For Bliss GVS shareholders, the immediate market impact was a sharp price rerating and a move into an overbought technical zone. The open offer price of ₹299 per share provides an additional reference point for investors assessing risk and reward after a 20% upper-circuit move.

Conclusion

Bliss GVS Pharma’s 20% upper-circuit surge followed the announcement that Anupam Rasayan will acquire about 43% stake for ₹1,369.51 crore, alongside a mandatory open offer for an additional 26% at ₹299 per share. The next key milestone implied in the disclosure is the open offer process for public shareholders, as Anupam Rasayan moves ahead with the transaction and its stated integration plan.